Home > EMCDDA–Europol Joint Report on a new psychoactive substance: N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA).

European Monitoring Centre for Drugs and Drug Addiction. (2017) EMCDDA–Europol Joint Report on a new psychoactive substance: N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA). Luxembourg: Joint Reports, Publications Office of the European Union. 15 p.

[img]
Preview
PDF (EMCDDA–Europol Joint Report on a new psychoactive substance) - Published Version
393kB

In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1- (cyclohexylmethyl)-1H-indazole-3-carboxamide, commonly known as ADB-CHMINACA, through a joint assessment. The two organisations launched a data collection on this substance for the preparation of a Joint Report as stipulated by Article 5.1 of the Council Decision. The Joint Report was submitted to the Council, the Commission and the European Medicines Agency on 3 July 2017.

Item Type:Evidence resource
Publication Type:Report
Drug Type:New psychoactive substance
Date:September 2017
Pages:15 p.
Publisher:Joint Reports, Publications Office of the European Union
Corporate Creators:European Monitoring Centre for Drugs and Drug Addiction
Place of Publication:Luxembourg
EndNote:View
Accession Number:HRB (Electronic Only)
Subjects:B Substances > New (novel) psychoactive substances
VA Geographic area > Europe

Repository Staff Only: item control page